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Abstract 
Objective: To evaluate the cost-effectiveness of radical prostatectomy (RP), external beam radiotherapy 
(EBRT) monotherapy, and EBRT+brachytherapy for men with very high-risk prostate cancer (VHRPC). 
Methods: Using a decision tree with embedded Markov process models, a cost-utility analysis was 
performed comparing the three treatment strategies for hypothetical cohorts of men with VHRPC. The 
base case time horizon was ten years; consistent with the maximum follow-up reported in the literature. 
The model parameters for distant metastases and mortality were derived from a multi-institutional study 
utilizing patient-level data. Costs were from a societal standpoint and health state utilities were obtained 
via standard gamble techniques. Incremental cost-effectiveness ratios were calculated per quality-
adjusted life year using a 3% discount rate. Sensitivity analyses (SA) addressed uncertainty in key 
variables. Findings: EBRT+brachytherapy was both cost-saving and more effective than both EBRT 
monotherapy and RP, strongly dominating both alternative treatment strategies. These results remained 
robust to extensive SA. 
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ABSTRACT 
 
 
 
Objective: To evaluate the cost-effectiveness of radical prostatectomy (RP), external beam 
radiotherapy (EBRT) monotherapy, and EBRT+brachytherapy for men with very high-risk 
prostate cancer (VHRPC). 
 
Methods: Using a decision tree with embedded Markov process models, a cost-utility analysis 
was performed comparing the three treatment strategies for hypothetical cohorts of men with 
VHRPC. The base case time horizon was ten years; consistent with the maximum follow-up 
reported in the literature. The model parameters for distant metastases and mortality were 
derived from a multi-institutional study utilizing patient-level data. Costs were from a societal 
standpoint and health state utilities were obtained via standard gamble techniques. Incremental 
cost-effectiveness ratios were calculated per quality-adjusted life year using a 3% discount rate. 
Sensitivity analyses (SA) addressed uncertainty in key variables.  
 
Findings: EBRT+brachytherapy was both cost-saving and more effective than both EBRT 
monotherapy and RP, strongly dominating both alternative treatment strategies. These results 
remained robust to extensive SA.  
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INTRODUCTION 
The American Cancer Society has estimated that nearly 192,000 new cases of 
adenocarcinoma of the prostate will be diagnosed in 2020, an increase of five percent from the 
prior year (American Cancer Society 2020). Prostate cancer is also expected to account for over 
33,000 deaths and will top the 2020 list of male cancer diagnoses at 21 percent with its closest 
competitor being lung cancer at only 13 percent. Twenty-five percent of these men present with 
high-risk disease, defined as cancers with high-grade pathology by the Gleason scoring system, 
i.e. Gleason scores of 8-10 out of 10 or a serum prostate specific antigen level greater than 20 
ng/mL (Parikh and Sher 2012). Further stratifying risk, seven to ten percent of all prostate cancer 
patients present with very high-risk disease with Gleason scores of 9 or 10, a particularly 
aggressive variant with a propensity for distant metastases and a high probability of prostate 
cancer-related death (Kishan et al. 2018).  
The optimal management of very high-risk prostate cancer has remained unclear but 
typically has involved the following three state-of-the art treatment options, supported by 
national standards of care: 1) robotic-assisted laparoscopic prostatectomy (RALP), i.e. surgical 
removal of the prostate with a pelvic lymph node dissection; 2) external beam radiotherapy 
(EBRT) monotherapy via image-guided intensity modulated radiotherapy (IG-IMRT) involving 
20 to 45 daily treatments, Monday through Friday; and 3) EBRT over 15 to 28 treatments 
followed by one or two transperineal brachytherapy (radioactive seed) interstitial implants, 
facilitating intense dose escalation to the prostate either via low dose rate radioisotopes such as 
Iodine-125 or high dose rate (HDR) radioisotopes such as Iridium-192 (National Comprehensive 
Cancer Network 2020). Both radiotherapy options are usually combined with 18 to 24 months of 
androgen deprivation therapy, which has been shown to improve survival in men with high-risk 
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disease (National Comprehensive Cancer Network 2020). Which of these three contemporary 
treatments for very high-risk prostate cancer provides the best outcomes remains unclear and this 
question has not been studied in any randomized controlled clinical trial. In a multi-institutional 
collaborative effort to more definitively evaluate the optimal treatment strategy for this very 
high-risk prostate cancer cohort, Kishan et al. (2018) recently reported the results of a 
retrospective cohort study of 1,809 patients with Gleason score 9-10 prostate cancer utilizing the 
individual patient data from 11 tertiary referral centers in the United States and one in Norway. 
At a median follow up ranging from 4.2 to 6.3 years for the three treatment groups, the 
combination EBRT plus brachytherapy boost group was shown to have a statistically significant 
improvement in prostate cancer-specific survival and a lower risk of distant metastases than 
either the EBRT monotherapy or RALP groups.  
In an environment of limited health care resources and with United States (US) national 
expenditures for prostate cancer care projected to reach over $20 billion in 2020, decision-
making authorities will increasingly require information on the cost-effectiveness of alternative 
treatment paradigms such as RALP, EBRT monotherapy and EBRT plus brachytherapy in order 
to inform health policy (Marriotto et al. 2011). The nontrivial differences in costs, efficacy and 
quality-of-life effects associated with the various treatment strategies to manage very high-risk 
prostate cancer suggest that quantifying the cost-effectiveness of these different treatment 
protocols is important. The purpose of this study was to evaluate the cost-effectiveness of RALP, 
EBRT monotherapy, and EBRT plus brachytherapy for patients with very high-risk prostate 
cancer based on the results of Kishan et al. (2018). 
  
METHODS 
  
 4 
Overview 
 In health care economies with limited budgets, cost-effectiveness analysis provides an 
analytical framework to compare the net benefit of a particular intervention to those benefits that 
others must forfeit as a result of reallocating resources. Cost-utility analysis considers the 
difference in incremental costs and quality-of-life-adjusted survival among treatment programs 
being considered, reported as the incremental cost-effectiveness ratio (ICER), which is compared 
to a willingness-to-pay threshold, usually determined by society or payers, and measured in 
dollars per additional quality-adjusted life year (QALY) gained. This represents the health 
benefits that may be given up by others due to any additional costs associated with a particular 
program. 
 
Decision Model 
Using TreeAge Pro software (Williamstown, MA), a decision tree with three embedded 
Markov models was developed to estimate the QALYs and the direct medical and non-medical 
costs associated with the three very high-risk prostate cancer treatment strategies from a societal 
perspective (Figure 1). As recommended by Levine, Ganz, and Haller (2007), the base-case time 
horizon of the cost-utility analysis was ten years, consistent with the maximum follow-up 
reported by Kishan et al. (2018) and not on results projected into the future. The Markov cycle 
length was set at six months to be temporally in line with the clinical treatment paradigms being 
evaluated.  
  
Markov Models 
            Markov simulations track patient transitions among mutually exclusive health states at 
fixed time cycles according to input probabilities. During each cycle, patients accumulate costs 
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and QALYs (Sonnenberg and Beck 1993). The patient cohort entered the model in the Alive 
Without Distant Metastasis (AWODM) health state and transitioned among health states of Alive 
With Distant Metastases (AWDM), Dead from Prostate Cancer and Dead from Other Causes, 
based on probabilities derived from Kishan et al. (2018) (Table 1). 
  
Survival Data and Analytic Methods 
A single study-based estimate of effectiveness was used because Kishan et al. (2018) is 
the largest published multi-institutional study to evaluate the comparative effectiveness of 
RALP, EBRT monotherapy and EBRT plus brachytherapy for patients with Gleason score 9-10 
prostate cancer treated according current national guidelines (National Comprehensive Cancer 
Network 2020). The adjusted five- and ten-year cumulative incidences for distant metastases, 
prostate-cancer specific mortality and all-cause mortality were used. These incidences were 
derived using Kaplan-Meier estimates with inverse probability of treatment weights for the 
intervals of years one through five years and six through ten, determined by utilizing propensity 
scores calculated with multinomial logistic regression with each treatment group set as the 
outcome and prostate-specific antigen level, age, cancer stage, and Gleason score as pretreatment 
prognostic covariates (Table 1). It was assumed that mortality from causes other than prostate 
cancer was equal to all-cause mortality minus prostate-cancer-specific mortality for the years one 
through five and six through ten cumulative estimates. The probabilities for each 5-year time 
interval were converted to 6-month rates using the formula rate = -ln(1-p)/t, where p equals the 
probability and t equals time. The six-month rate was then converted back to a six-month 
probability to coincide with the selected Markov cycle length using the formula, probability = 1-
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e(-rt), where r equals rate and t equals time. The model was then calibrated to accurately match the 
mortality and distant metastases risks reported in the study (Kishan et al. 2018). 
  
Direct Medical and Non-Medical Costs 
Consistent with a societal perspective, both direct medical and non-medical costs were 
considered. If necessary, costs were inflated to 2019 US dollars using the medical care 
component of the US Chained Consumer Price Index (United States Bureau of Labor Statistics 
2020).  
Direct medical costs for the AWODM health state of the EBRT monotherapy and EBRT 
plus brachytherapy treatment cohorts were obtained from the Centers for Medicare and Medicaid 
Services Physician Fee Schedule national payment amount and are shown in Tables 2 and 3 
(Centers for Medicare & Medicaid Services 2020). For any radiotherapy treatment group, these 
costs included a comprehensive-level consultation with a radiation oncologist, treatment 
simulation and planning, dosimetry, ongoing physics support, treatment delivery, and weekly 
patient management. Patients in the EBRT monotherapy group were treated with a moderately 
hypofractionated EBRT program using IG-IMRT to a total dose of 60 Gy in 20 fractions of 3 Gy 
each, delivered on a five days per week schedule. Those in the EBRT plus brachytherapy group 
received EBRT in a similar fashion but to a final dose of 37.5 Gy in 15 fractions of 2.5 Gy each 
delivered five days per week followed by a single HDR Ir-192 brachytherapy treatment of 15 
Gy. It was assumed that half of the brachytherapy cohort would undergo the implant at a 
hospital-based outpatient surgery department and half at an ambulatory surgery center in order to 
capture the cost differences associated with these diverse points of care (Hall, Schwartzman, 
Zhang, and Liu 2017). Based on National Comprehensive Cancer Network (NCCN) guidelines, 
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all patients in the two radiotherapy treatment groups received a total of 24 months of androgen 
deprivation therapy by intramuscular leuprolide injections delivered on a once every three-month 
schedule (Table 4). The direct medical costs of RALP were obtained from a retrospective, cross-
sectional study of hospital discharges based on national inpatient sample data of the Healthcare 
Cost and Utilization Project (HCUP), using Medicare reimbursement adjusted by the appropriate 
cost-to-charge ratios published by HCUP (Mukherjee 2019). As per Kishan et al. (2018), 33.3 
percent of the RALP cohort received androgen deprivation therapy, which was assumed to 
consist of a total of six months of leuprolide, consistent with NCCN guidelines (National 
Comprehensive Cancer Network 2020). In addition, 42.8 percent of the RALP group received 
adjuvant or salvage EBRT (Kishan et al. 2018). Adjuvant/salvage EBRT was carried out using 
conventional fractionation and consisted of a total dose of 70 Gy delivered in 35 fractions of 2 
Gy each on a Monday through Friday schedule with the associated direct medical costs shown in 
Table 5 (National Comprehensive Cancer Network 2020). The direct medical costs of RALP 
incurred during the first Markov cycle were $28,822; i.e., $18,974 for the procedure plus $9,400 
and $447 for the proportions of the cohort receiving adjuvant/salvage EBRT and androgen 
deprivation therapy, respectively. 
The direct medical costs for the AWDM health state are shown in Table 6 and were 
derived from a deterministic, decision analytic model that estimated the direct medical costs 
associated with the management of prostate cancer including metastatic disease from a US 
commercial-payer perspective (Gustavsen, Gullet, Cole, Lewine, and Bishoff 2019). In order to 
account for the differences in costs between patients with castrate-naïve disease, which is still 
responsive to androgen deprivation therapy, and castrate-resistant disease, which is resistant to 
androgen deprivation therapy and more expensive to manage, the total direct medical costs for 
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the AWDM were weighted by the proportion of patients with either castrate-naïve or castrate-
resistant metastatic prostate cancer (Sathianathan 2019). The costs associated with follow-up 
testing and office visits after definitive treatment are the same for all three treatment strategies 
and therefore, were not modelled (National Comprehensive Cancer Network 2020). Other 
potential downstream costs to manage potential late complications of each treatment modality 
were not considered since there is a paucity of data to accurately compare longer-term toxicities 
of these three treatment approaches in the modern era using state-of-the art treatment 
technologies (Yu and Hamstra 2017). 
Direct non-medical costs were estimated for patient transportation and patient-related 
time lost from productive work or leisure associated with treatment and office visits (Table7). 
Direct non-medical costs of patient transportation for treatments included the average number of 
miles traveled to receive care and parking (Longacre, Neprash, Shippee, Tuttle, and Virnig 2019; 
Inrix 2017). Travel costs for any treatment-related visit were estimated using the AAA average 
cost-per-mile based on the average number of miles driven per year for men 55 to 64 years old 
which was found to be $0.58/mile (AAA Association 2018). The AAA cost/mile was multiplied 
by 22.6 miles, the median round-trip miles traveled for cancer care, totaling $18.11 per round-
trip (Longacre et al. 2019). The total transportation cost for each treatment strategy was obtained 
by multiplying the number of visits associated with each strategy by the average cost per round-
trip.  
The median age of patients in the Kishan et al. study (2018) was 61 years and the value 
of patients’ time lost from productive work or leisure was determined from the median hourly 
wage rate for men of 54 to 61 years old, assuming 40 hours/week (U.S. Bureau of Labor 
Statistics 2019). The median time spent in round-trip travel for any treatment-related visit was 
 9 
40.6 minutes based on a study evaluating the travel distance to cancer-care facilities among rural 
and urban cancer patients (Longacre et al. 2019). The time that was allotted for the each of the 
various types of treatment-related visits were obtained from the literature or based on expert 
opinion and included the following: any initial physician consultation, 1 hour; post-operative 
visit, 0.5 hour; total brachytherapy procedure time, 6 hours; RALP hospital admission, 13.6 
hours calculated from 1.7 days mean length of stay with 8 hours per day assumed to be lost from 
work or leisure (Yu et al. 2012; Weinstein, Siegel, Gold, Kamlet, and Russell 1996). The time 
lost from work or leisure associated with convalescence from brachytherapy and RALP 
procedures were 3 days and 42 days at 8 hours per day, respectively (Mechow et al. 2018; 
UCLA Health 2020). 
  
Health State Utilities 
Patient preferences for health states associated with organ-confined and metastatic 
prostate cancer were obtained from the literature and were elicited from members of the general 
public using standard gamble techniques (Stewart, Lenert, Bhatnagar, and Kaplan 2005). The 
disutility associated with potential late complications of each treatment modality was not 
evaluated since the probability of late complications remains unclear in the era of modern 
prostate cancer treatment modalities and was not modelled (Yu and Hamstra 2017). The utility 
values for the AWDM and AWODM health states are shown in Table 1.  
  
Cost-Effectiveness Analysis 
Expected costs and QALYs were calculated for each treatment strategy. The ICER was 
obtained by dividing the incremental cost of the more expensive strategy by its incremental 
benefit in QALYs. A three percent annual discount rate was used for costs and benefits to foster 
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comparability of the results with those of many other economic evaluations (Muennig 2008). As 
recommended by Neumann, Cohen, and Weinstein (2014), willingness-to-pay values of $50,000, 
$100,000, and $200,000 per additional QALY gained were considered as thresholds for cost-
effectiveness. 
  
Sensitivity Analyses 
Deterministic sensitivity analyses were carried out to evaluate the effect of plausible 
changes in key variables on the ICER, including costs, health state utility values, annual discount 
rate and the probabilities of distant metastasis, prostate cancer-specific mortality, and other-cause 
mortality. Probabilistic sensitivity analysis was conducted using Monte Carlo simulation on all 
parameters, which were randomly and simultaneously sampled from defined probability 
distributions over 1,000 iterations. Sampling from Beta distributions, mortality, and distant 
metastases probabilities were varied by their reported 95 percent confidence intervals while 
health state utility values were studied over their reported standard deviations. Direct costs of 
RALP and all radiotherapy treatment programs were varied by plus or minus 25 percent to 
approximate two standard deviations and a normal distribution was used because these were 
based on solid estimates obtained from Medicare reimbursement (Singer 2006). The costs of 
managing metastatic disease were Medicare estimates obtained using a decision analytic model 
with a higher degree of uncertainty. Therefore, these costs were doubled and halved to 
approximate a wider confidence interval and a Gamma distribution was used with standard 
deviation of (high value-low value)/4 (Singer 2006).  
  
RESULTS 
Model Validation 
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The results generated by the model were found to accurately mirror the five- and ten-year 
distant metastasis, prostate cancer-specific survival and other-cause mortality risks reported by 
Kishan et al. (2018).  
  
Base Case Analysis 
The results of the base case analysis are shown in Table 8. EBRT plus brachytherapy 
resulted in a net savings of $12,262 and $31,989 versus EBRT monotherapy and RALP, 
respectively. This reflects the higher upfront costs associated with RALP and the discounted 
savings due to lower cumulative costs to manage progressive metastatic disease for the EBRT 
plus brachytherapy group compared to the other strategies. EBRT + brachytherapy yielded an 
incremental 1.30 and 1.12 QALYs over EBRT monotherapy and RALP, respectively. EBRT + 
brachytherapy was both cost-saving and more effective than both EBRT monotherapy and RALP 
and therefore, strongly dominated both alternative treatment strategies.   
Sensitivity Analysis 
The results of the one-way deterministic sensitivity analysis are illustrated in the tornado 
diagrams shown in Figure 2. Tornado diagrams are graphical representations of all one-way 
sensitivity analyses results for all the variables studied, presented in one figure. The gray vertical 
line shows the base case ICER. The horizontal bars represent the ICER values over the range of 
the variable values studied. The ICER for EBRT plus brachytherapy was most sensitive to the 
total direct costs associated with the AWDM health state. However, regardless of society’s 
willingness-to-pay for an additional QALY gained, EBRT plus brachytherapy strongly 
dominated both competing strategies on deterministic sensitivity analysis of all key variables 
over plausible ranges.  
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The result of the probabilistic sensitivity analysis is illustrated in the cost-effectiveness 
acceptability curve (Figure 3). An acceptability curve illustrates the percentage of Monte Carlo 
simulations that each treatment strategy is preferred over the others at a certain societal 
willingness-to-pay for an additional QALY. For the ten-year time horizon EBRT plus 
brachytherapy was expected to be the optimal and preferred strategy in 99% of the simulations at 
a willingness-to-pay of $50,000/QALY. 
 
DISCUSSION 
Cost-effectiveness analysis provides the framework for an evidence-based approach to 
the comparison of the costs and quality-of-life adjusted clinical outcomes of the three modern 
treatment programs for very high-risk prostate cancer. Through the use of sensitivity analysis, it 
also allows the investigator to evaluate the base case results over a wide range of assumptions, 
which may confirm or lead to modifying the base case conclusions. Using the actual follow up 
interval reported in the Kishan et al. (2018) multi-institutional study, it was found that EBRT 
plus brachytherapy saved costs, improved quality-of-life adjusted survival, and strongly 
dominated its comparator treatment paradigms of EBRT monotherapy and RALP. This 
conclusion was supported by the results of the probabilistic sensitivity analysis, which found 
EBRT plus brachytherapy to be the preferred treatment strategy in 99 percent of the simulations 
at a willingness-to-pay threshold of $50,000/QALY. This suggests that there is a high likelihood 
that EBRT plus brachytherapy either dominates its comparators or is cost-effective over a ten-
year time horizon. Deterministic sensitivity analysis also demonstrated that the model was most 
sensitive to total direct costs associated with the management of distant metastatic disease 
highlighting the importance of the reduced risk of distant metastasis seen with the EBRT plus 
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brachytherapy cohort despite similar overall (all-cause) survival of the three treatment cohorts at 
ten years. 
The policy implications of this study are not insignificant. There are approximately 
200,000 new cases of prostate cancer diagnosed annually in the United States and nearly 1.3 
million globally (American Cancer Society 2020; Rawla 2019). About 20,000 and 130,000 of 
these cases are expected to be very high risk in the US and worldwide, respectively (Kishan 
2018). Based on the results of this cost-effectiveness analysis and considering the proportional 
usage of RALP versus EBRT reported by Kishan et al. (2018), the use of EBRT plus 
brachytherapy in this cohort could decrease US health care expenditures by about $431 million 
annually. Annual global health care expenditures could potentially be reduced over a range of 
about $16 billion to $42 billion, depending on the existing worldwide treatment mix of EBRT 
monotherapy and RALP for very high-risk prostate cancer, which is not well known. 
There are no other studies that have evaluated the cost-effectiveness of EBRT plus 
brachytherapy versus EBRT monotherapy and RALP for organ-confined, very high-risk prostate 
cancer. However, Parikh and Sher (2012) developed a decision model to analyze the comparative 
effectiveness of primary radiotherapy versus radical prostatectomy for patients with high-risk 
prostate cancer. They evaluated the difference in QALYs associated with three treatment 
cohorts: EBRT with androgen deprivation therapy, prostatectomy plus adjuvant EBRT, and 
trimodality therapy consisting of radical prostatectomy, adjuvant EBRT and androgen 
deprivation therapy. Using a lifetime horizon, they found that EBRT with androgen deprivation 
therapy may be superior to radical prostatectomy plus adjuvant EBRT and that trimodality 
therapy may lower risks of progressive disease for a significant number of men. However, this 
study also included patients with Gleason score 8 disease, consistent with a high-risk group but 
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not the very high-risk group. The investigators did not discount future health benefits to their 
present value and neither  evaluated treatment-related costs nor the potential impact of 
brachytherapy on the results.  
The current cost-effectiveness analysis being presented has some limitations. First, 
although others have compared the outcomes of the three treatments that were studied, a decision 
was made to use mortality and distant metastasis data from one large multi-institutional 
retrospective cohort study. In another retrospective cohort study, Ennis, Hu, Ryemon, Lin, and 
Mazumdar (2018) assessed the overall survival of high-risk patients treated by radical 
prostatectomy, EBRT with androgen deprivation therapy, and EBRT plus brachytherapy with or 
without androgen deprivation therapy using the National Cancer Database. After adjusting for 
prostate cancer prognostic factors, other competing medical comorbidities and socioeconomic 
characteristics, these investigators found EBRT monotherapy to be associated with inferior 
overall survival but there was no statistical difference in overall survival between the EBRT plus 
brachytherapy and radical prostatectomy cohorts. These results are comparable to those of 
Kishan et al. (2018), which showed an overall survival advantage for EBRT + brachytherapy 
before 7.5 years of follow up but similar overall survival for all three treatment cohorts at ten 
years, possibly reflecting an early prostate cancer-specific mortality advantage for EBRT plus 
brachytherapy that eventually was trumped by increasing other-cause mortality in later years. 
However, Ennis et al. (2018) did not limit their analysis to the Gleason score 9-10 very high-risk 
group and did not present data on prostate-cancer-specific mortality or the risk for development 
of distant metastases. These omissions provided additional support for the sole use of the Kishan 
et al. (2018) study, which also utilized patient-level data. 
 15 
Second, the distant metastases, prostate cancer-specific mortality and other-cause 
mortality data reported by Kishan et al. (2018) was limited to ten years and this cost-
effectiveness analysis was therefore, limited to this time horizon (Levine et al. 2007). Although a 
lifetime horizon was not evaluated in this cost-effectiveness analysis at this time, the fact that 
there are no anticipated dramatic differences in downstream costs or quality-of-life effects 
indicates that the base case results are unlikely to change over longer time horizons. Despite the 
fact that the overall survival of EBRT plus brachytherapy and RALP equalized by ten-years, the 
significant difference in the risk of distant metastases between the EBRT plus brachytherapy 
group compared to the other two treatment groups remained robust and review of the Kaplan-
Meier curves shows this difference to continue to widen over time (Kishan et al 2018). Since the 
cost of managing distant metastatic disease appears to have one of the largest relative impacts on 
cost-effectiveness, it seems likely that the strategy of EBRT plus brachytherapy would only 
become increasingly preferred over the other treatment options over a lifetime horizon. 
Third, there was some uncertainty surrounding the costs used in the model. The direct 
medical costs for EBRT plus brachytherapy, EBRT monotherapy, adjuvant/salvage EBRT after 
RALP and androgen deprivation therapy were calculated using a micro-costing approach using 
the Centers for Medicare and Medicaid Services Physician Fee Schedule, a well-established 
source with a high degree of certainty. Similarly, the direct medical costs associated with the 
AWODM health state for RALP were based on Medicare reimbursement. However, the costs 
associated with the AWDM for all treatment groups were obtained from a costing study using 
deterministic decision analytic techniques. Despite reporting Medicare estimates for the cost of 
managing distant metastatic disease, it is possible that this study could have a higher degree of 
uncertainty. To address this uncertainty, a wider confidence interval was used for sensitivity 
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analysis of these costs and, despite this, the ICER for EBRT plus brachytherapy never became a 
positive number. 
CONCLUSION 
Using the actual follow-up interval reported by Kishan et al. (2018), EBRT plus 
brachytherapy strongly dominated the strategies of EBRT monotherapy and RALP for patients 
with very high-risk prostate cancer. Since the long-term incremental costs and distant metastases 
risks are unlikely to dramatically change after a decade of follow-up, it is likely that EBRT plus 
brachytherapy will either dominate the comparator strategies or remain cost-effective given 
contemporary willingness-to-pay thresholds of $50,000-$200,000 per QALY over a lifetime 
scenario.  
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 Figure 1. Decision Tree with three embedded Markov models for EBRT + brachytherapy, EBRT 
monotherapy, and RALP. Abbreviations: EBRT: external beam radiotherapy monotherapy; 
EBRT+BT: external beam radiotherapy with brachytherapy boost; RALP: robotic assisted 
laparoscopic prostatectomy. 
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Table 1. Model Parameters, Ranges Studied and Distributional Assumptions 
Probability   
Treatment 
Cohort 
Interval 
(years) 
Base 
Case 
Value 
(mean) 
Range 
Studied* 
 
Standard 
Deviation  
Distribution 
for PSA 
Reference 
Number  
Distant Metastasis 
RALP 0-5 0.24 0.19-0.30 0.028 
Beta 8 
 >5-10 0.46 0.38-0.54 0.04 
EBRT 0-5 0.24 0.20-0.28 0.02 
 >5-10 0.44 0.38-0.50 0.03 
EBRT+BT 0-5 0.08 0.05-0.11 0.015 
 >5-10 0.13 0.09-0.17 0.02 
Prostate Cancer Specific Mortality 
RALP 0-5 0.12  0.08-0.17 0.023 
Beta 8 
 >5-10 0.23 0.18-0.30 0.03 
EBRT 0-5 0.13 0.08-0.19 0.028 
 >5-10 0.26 0.20-0.32 0.03 
EBRT+BT 0-5 0.03 0.01-0.05 0.01 
 >5-10 0.13 0.08-0.19 0.028 
Death from Other Causes 
RALP 0-5 0.05 0.04-0.06 0.05 
Beta 8 
 >5-10 0.09 0.07-0.11 0.01 
EBRT 0-5 0.05 0.04-0.06 0.05 
 >5-10 0.13 0.10-0.16 0.04 
EBRT+BT 0-5 0.07 0.05-0.09 0.01 
 >5-10 0.18 0.14-0.24 0.025 
Health State Utility Values 
Alive with 
Distant 
Disease 
 
0.25 0.14-0.36 0.11 
Beta 
 
22 Alive 
without 
distant 
disease 
 
0.81 0.63-0.99 0.18 
Annual Discount Rate 
Rate  0.03 0.005-0.05  Uniform 13 
Abbreviations: RALP, Robotic-assisted laparoscopic prostatectomy; EBRT, external beam 
radiotherapy; EBRT + BT, external beam radiotherapy with brachytherapy boost; PSA, 
Probabilistic Sensitivity Analysis. *95% confidence interval when provided. 
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Table 2. Direct Medical Costs of External Beam Radiotherapy Monotherapy3 
Service 
CPT 
code 
No. 
Units 
2019 CMS 
physician fee 
schedule 
Medicare 
National 
Payment 
Amount, US $ 
Reimbursement 
per unit, US $ 
Reimbursement 
Total, US $ 
Initial New Patient 
office visit-
comprehensive 99204 1 
167.09* 
132.09** 147.14 147.14 
Physician 
Prescription 
Treatment Plan; 
Complex 77263 1 174.31 174.31 174.31 
Special Treatment 77470 1 136.78 136.78 136.78 
IMRT Plan-
Including DVH for 
Target & Critical 
Structures 77301 1 1,949.20 1,949.20 432.71 
IMRT Multi-Leaf 
Collimator 77338 1 497.31 497.31 497.31 
Basic Dosimetry 
calculation 77300 2 67.85 67.85 135.70 
IMRT Treatment 
delivery- single or 
multiple fields G6015 20 369.92 369.92 7,398.40 
Daily CT image-
guidance 77014 20 124.51 124.51 2,490.20 
Radiation Treatment 
Management 
(weekly physician 
on-treatment visit) 77427 4 196.33 196.33 785.32 
Continuing physics 
consultation  77336 4 81.20* 81.20 139.66 
Total Direct Medical Cost for EBRT Monotherapy 13,854 
Abbreviations: EBRT, external beam radiotherapy; IMRT, image-guided intensity modulated 
radiotherapy; DVH: dose volume histogram.  
*fee for freestanding facilities (43% of radiotherapy centers)26 
**fee for hospital-based facilities (57% of radiotherapy centers)26 
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Table 3. Direct Medical Costs of External Beam Radiotherapy + Brachytherapy Boost3 
Service 
CPT 
code 
No. 
Units 
2019 CMS 
Physician Fee 
Schedule Medicare 
National Payment 
Amount, US $ 
Reimbursement 
per unit, US $ 
Reimbursement Total, 
US $ 
Initial New Patient Office 
Visit-comprehensive 99204 1 
167.09* 
132.09** 147.14 147.14 
Physician Prescription 
Treatment Plan; Complex 77263 1 174.31 174.31 174.31 
Special Treatment 77470 1 136.78 136.78 136.78 
IMRT Plan-Including 
DVH for Target & Critical 
Structures 77301 1 1,949.20 432.71 432.71 
IMRT Multi-Leaf 
collimator 77338 1 497.31 497.31 497.31 
Basic Dosimetry 
calculation 77300 1 67.85 67.85 67.85 
IMRT treatment delivery- 
single or multiple fields G6015 15 369.92 369.92 5,548.80 
Daily CT image-guidance 77014 15 124.51 124.51 1,867.65 
Radiation Treatment 
Management (weekly 
physician on-treatment 
visit) 77427 3 196.33 196.33 588.99 
Continuing physics 
consultation 77336 3 81.20* 81.20 104.75 
Total for EBRT Component 11,082.78 
Simulation; 3-Dimensional 
HDR 77295 1  498.04 498.04 
Remote afterload HDR 77772 1  922.45 922.45 
Simulation; simple 77280 1  283.30 283.30 
Transperineal placement, 
needle/catheters into 
Prostate 55875 1  801.19 801.19 
Treatment device; simple 77332 1  48.36 48.36 
Hospital Outpatient and 
Ambulatory Surgery 
Center Facility Fee§  1  2,967 2,967 
Total for Single brachytherapy HDR Implant 5,520 
Total Direct Medical Cost of EBRT plus brachytherapy boost 16,603 
Abbreviations: EBRT, external beam radiotherapy; IMRT, image-guided intensity modulated radiotherapy; 
DVH: dose volume histogram; HDR, High Dose Rate brachytherapy. *Fee for freestanding facilities (43% of 
radiotherapy centers).26 **Fee for hospital-based facilities (57% of radiotherapy centers).26 §50% Hospital 
Outpatient/50% Ambulatory Surgery Centers rates6 
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Table 4. Direct Medical Cost of Androgen Deprivation Therapy per 6-Month Markov Cycle3 
Service CPT code No. Units/ 
6-month 
Cycle 
2019 CMS Physician 
Fee Schedule Medicare 
National Payment 
Amount/unit, US $ 
Reimbursement 
Total, US $ 
Drug cost of leuprolide  HCPCS 
code 
J9217 6 235.37 1,412.22 
Hormone antineoplastic 
subcutaneous or 
intramuscular injections 
(administration of drug) 
96402 2 32.12 64.24 
Total Cost of Androgen Deprivation Therapy per 6-Month Markov Cycle 1,476 
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Table 5. Direct Medical Costs of Adjuvant/Salvage EBRT (42.8% of RALP Group)3 
Service 
CPT 
code 
No. 
Units 
2019 CMS 
physician fee 
schedule 
National 
Payment 
amount, US 
$ 
Reimbursement 
per unit, US $ 
Reimbursement 
Total, US $ 
Initial New Patient 
Office Visit- 
comprehensive 99204 1 
167.09* 
132.09** 147.14 147.14 
Physicians 
Prescription Treatment 
Plan; Complex 77263 1 174.31 174.31 174.31 
Special Treatment 77470 1 136.78 136.78 136.78 
IMRT Plan-including 
DVH for Target and 
Critical Structures 77301 1 1,949.20 1949.20 1,949.20 
IMRT Multi-Leaf 
Collimator 77338 1 497.31 497.31 497.31 
Basic Dosimetry 
Calculation 77300 2 67.85 67.85 135.70 
IMRT Treatment 
delivery- single or 
multiple fields G6015 35 369.92 369.92 12,947.20 
Daily CT Image-
Guidance 77014 35 124.51 124.51 4,257.85 
Radiation Treatment 
Management (weekly 
physician on-treatment 
visit) 77427 7 196.33 196.33 1,374.31 
Continuing Physics 
Consultation 77336 7 81.20* 81.20 244.41 
Total Direct Medical Costs for Adjuvant/Salvage EBRT 21,964 
Abbreviations: EBRT, external beam radiotherapy; IMRT: image-guided intensity modulated 
radiotherapy; DVH: dose volume histogram RALP, robotic-assisted laparoscopic 
prostatectomy. *Fee for freestanding facilities (43% of radiotherapy centers).26 **Fee for 
hospital-based facilities (57% of radiotherapy centers).26 
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  Table 6. Total Direct Medical Costs of the Alive With Distant Metastases Health State 
  per 6-Month Markov Cycle 
 
% of Total 
Cost 
Cost per 6-month 
Markov Cycle, 
Adjusted to 2019 US $* 
References 
Castrate Naïve Disease 94.25 1,535 
5, 19 Castrate Resistant Disease 5.75 61,053 
Weighted 6-month Markov Cycle Cost 5,053 
*Adjusted from 2018 to 2019 US dollars using the medical care component of the US Chained 
Consumer Price Index.24  
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Table 7. Direct Non-Medical Costs: Value of Patients’ Time Lost From Work or Leisure and Transportation Expenses 
 EBRT Monotherapy EBRT + Brachytherapy RALP Adjuvant or Salvage 
EBRT 
Androgen Deprivation 
Therapy per 6 Month 
Markov Cycle^ 
Value of Patient 
Time Lost 
     
 Hours/ 
Unit 
No. Cost 
US$§ 
Hours/ 
Unit 
No. 
Units 
Cost 
US$§ 
Hours/ 
Unit 
No. 
Units 
Cost US$§ Hours/ 
Unit 
No. 
Units 
Cost 
US$§ 
Hours/ 
Unit 
No. 
Units 
Cost 
US$§ 
Initial Physician 
Consultation 1 1 28.43 1 1 28.43 1 1 28.43 1 1 28.43    
Daily EBRT 
Treatments or 
Office Visit 0.5 20 284.25 0.5 15 213.19    0.5 35 497.53 0.5 2 28.43 
Pre-operative Visit    1 1 28.43 1 1 28.43       
Brachytherapy 
Procedure    6 1 170.58          
Post-Operative 
Visit    0.5 1 14.21 0.5 1 14.21       
Mean Hospital 
Length of Stay*       8 1.7 386.58       
Mean Time Out of 
Work**    8 3 682.20 8 42 9,550.80       
Travel Time10 0.667 21 398.15 0.667 19 360.23 0.667 4** 75.84 0.667 36 682.66 0.667 2 37.93 
Total   710.83   1,497.27   10,084.29   1,208.62   66.36 
Transportation 
Expenses      
Office or hospital 
visits  21 380.31  19 344.09  4 72.44  36 651.96  2 36.22 
Total Direct Non-
Medical Costs  
 
 1,091   1,841   10,157   1,861   103 
Abbreviations: EBRT, external beam radiotherapy; RALP, robotic-assisted laparoscopic prostatectomy. §Median gender-specific wage rate is $28.43/hour.25; ^ EBRT 
monotherapy and EBRT + brachytherapy patients received a total of 24 months of androgen deprivation therapy.15 Adjuvant or salvage EBRT patients received 6 
months of ADT.15 * Mean hospital length of Stay for RALP was 1.7 days and assumed 8 hours/day lost from work or leisure.29  **Assumed to be 8 hours/day of 
convalescence (3 days for brachytherapy and 42 days for RALP)12,23  **Includes roundtrip to hospital for RALP. 
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Table 8. Base Case Results 
 Strategies 
 EBRT + 
Brachytherapy 
EBRT 
Monotherapy 
RALP 
Cost, US $ 29,414 41,676 61,403 
Incremental Cost, US $ 0 12,262 31,989 
Effectiveness  5.85 4.54 4.73 
Incremental 
Effectiveness 0 -1.30 -1.12 
Incremental Cost-
Effectiveness Ratio 
(ICER) 0 -9,399 -28,575 
Interpretation 
 
Strongly dominated 
by EBRT + BT 
Strongly dominated 
by EBRT + BT 
Abbreviations: EBRT, external beam radiotherapy; RALP, robotic-assisted laparoscopic 
prostatectomy. 
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Figure 2. Tornado diagrams of one-way deterministic sensitivity analysis of key variables for A.) 
EBRT + Brachytherapy versus EBRT monotherapy and, B.) EBRT + Brachytherapy versus RALP. 
Abbreviations: EBRT: external beam radiotherapy monotherapy; EBRT+BT: external beam 
radiotherapy with brachytherapy boost; RALP: robotic assisted laparoscopic prostatectomy; EV: 
expected value 
A. 
B. 
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Figure 3. Cost-effectiveness acceptability curve for EBRT, EBRT+ BT, and robotic assisted 
laparoscopic radical prostatectomy at a willingness-to-pay of $50,000 to $200,000/QALY. 
Abbreviations: EBRT: external beam radiotherapy monotherapy; EBRT+BT: external beam 
radiotherapy with brachytherapy boost  
